Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$0.22.

  • Anika Therapeutics' EPS (Basic) rose 8916.26% to -$0.22 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.38, marking a year-over-year increase of 6505.14%. This contributed to the annual value of -$3.83 for FY2024, which is 3209.22% up from last year.
  • Latest data reveals that Anika Therapeutics reported EPS (Basic) of -$0.22 as of Q3 2025, which was up 8916.26% from -$0.33 recorded in Q2 2025.
  • Anika Therapeutics' EPS (Basic)'s 5-year high stood at $0.45 during Q2 2021, with a 5-year trough of -$4.3 in Q4 2023.
  • In the last 5 years, Anika Therapeutics' EPS (Basic) had a median value of -$0.31 in 2024 and averaged -$0.59.
  • In the last 5 years, Anika Therapeutics' EPS (Basic) skyrocketed by 18333.33% in 2021 and then plummeted by 116470.59% in 2023.
  • Over the past 5 years, Anika Therapeutics' EPS (Basic) (Quarter) stood at -$0.4 in 2021, then grew by 15.0% to -$0.34 in 2022, then crashed by 1164.71% to -$4.3 in 2023, then soared by 65.35% to -$1.49 in 2024, then surged by 85.23% to -$0.22 in 2025.
  • Its last three reported values are -$0.22 in Q3 2025, -$0.33 for Q2 2025, and -$0.34 during Q1 2025.